Die USBank Citigroup hat Roche von "Neutral" auf "Buy" hochgestuft und das Kursziel von 210 auf 300 Franken angehoben. Analyst Andrew Baum verwies in einer Studie vom Mittwoch darauf dass er sei...
Roche files next-generation Rituxan in USA, EU…
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!ZURICH, May 15 (Reuters) - Swiss drugmaker Roche hopes data published this week will show it has a viable fol…
ZURICH Reuters Swiss drugmaker Roche hopes data published this week will show it has a viable followon product to help fend off cheaper competition for its bestselling cancer drug which loses patent…
